Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arizona for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arizona only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arizona (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Allan Espinosa Morazan (NPI 1225350788)

Field	Value
Entity Type	Individual
Organization	Allan Espinosa Morazan
Address	5430 Landmark Ln
City	Prescott
State	AZ
ZIP	86301
Taxonomy	Medical Oncology Physician
NPI Enumerated	February 24, 2010

Payer Source	Total Paid
Medicare	$2.2M
Medicaid	$0

Key Findings

Practice appears to be an infusion-centric oncology practice driven by high-volume immunotherapy and chemotherapy administration: J9271 (Injection, pembrolizumab) alone accounts for $1.2M in Medicare revenue across 29K claims and represents 56.5% of the provider's Medicare revenue, and procedural chemotherapy codes such as 96413 (646 claims, $64K) and add-on/infusion codes 96411 and 96417 also appear throughout the top codes. The mix of high-volume drug administration codes and multiple chemotherapy administration add-ons indicates daily infusion services are a core operational focus rather than a primarily consultative or procedural surgery practice.

Revenue is highly concentrated: the top 3 Medicare codes by revenue account for 68.1% of this provider's total Medicare revenue. Those top contributors are J9271 ($1.2M, 56.5%), 78815 ($142.7K, 6.6%), and 99215 ($105.8K, 4.9%), signaling reliance on a small set of high-value services for the majority of Medicare income.

On several injectable/infusible products this provider ranks well above peers nationally, consistent with a regional or niche specialty role. For example, J9271 ranks #135 of 1841 providers nationally (93th percentile; notably above typical national volume for this code), J9305 (pemetrexed) ranks #1 of 33 providers nationally (100th percentile; notably above typical national volume for this code), and 96523 (irrigation of venous access device) ranks #1 of 1643 providers nationally (100th percentile; extreme outlier), which together point to unusually high procedural throughput for drug administration and vascular access maintenance.

Office visit volume is also elevated, suggesting substantial ongoing management of complex patients rather than sporadic consultations. 99215 shows 808 claims and $105.8K revenue (4.9%) and ranks #517 of 145531 providers nationally (100th percentile; extreme outlier), while 99214 has 931 claims and $83.8K revenue (3.9%) and ranks #13676 of 479517 providers nationally (97th percentile; notably above typical national volume for this code), consistent with frequent high-complexity follow-up visits.

Imaging and staging services are a meaningful secondary revenue stream, supporting active cancer management and longitudinal monitoring. 78815 (PET/CT) contributes $142.7K (6.6%) with 128 claims and ranks #1595 of 6566 providers nationally (75th percentile; typical, unremarkable volume for this code), and A9552 appears with 150 claims and $18K (0.8%) and ranks #441 of 2411 providers nationally (82th percentile; typical, unremarkable volume), indicating regular use of PET imaging in the care pathway.

This provider's payer mix is effectively single-payer Medicare: lifetime Medicare revenue is $2.2M and there is no Medicaid billing on file (none). The absence of Medicaid activity concentrates payer exposure and suggests that contracting, reimbursement policy changes, or Medicare payment volatility would disproportionately affect this practice's revenue.

Tenure is long enough to have established referral and treatment patterns: the NPI was enumerated 2010-02-24 (~16 years ago). This longevity, coupled with sustained high volumes in infusion and complex evaluation-and-management codes, supports the interpretation of a stable, mature oncology practice.

The provider also records meaningful use of supportive care agents and biosimilars, reflecting comprehensive oncology throughput beyond primary anti-cancer drugs. Examples include J0185 (aprepitant) with 22.8K claims and $22.8K revenue ranking #48 of 819 providers nationally (94th percentile; notably above typical national volume for this code), Q5118 (bevacizumab-bvzr) with $68.8K (3.2%) ranking mid-range among peers, and J0897 (denosumab) with $73.4K (3.4%) at a typical-to-modest percentile, indicating integrated supportive-care services and biosimilar utilization within the infusion suite.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

68 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	29,000	$40	$1.2M
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	130	$1,120	$142.7K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	810	$130	$105.8K
J9305	Injection, pemetrexed, not otherwise specified, 10 mg	8,260	$10	$90.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	930	$90	$83.8K
J0897	Injection, denosumab, 1 mg	4,080	$20	$73.4K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	2,990	$20	$68.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	650	$100	$64K
J1437	Injection, ferric derisomaltose, 10 mg	2,000	$20	$32K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	220	$130	$29.9K

Showing 1–10 of 68

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 68 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arizona Distribution

Allan Espinosa Morazan — 11 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arizona

Full comparison — all codes billed, vs. state median

68 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	3	80	10,000	$40	$487.4K
J0897	98	260	2,940	$20	$115.6K
78815	32	160	60	$710	$75.8K
Q5118	4	20	1,290	$20	$44.4K
Q5122	8	10	410	$90	$36.5K
J1437	4	20	1,600	$20	$26.5K
J9305	1	10	1,420	$10	$26.4K
96413	19	230	190	$100	$24.8K
J0881	14	50	7,000	$1	$23.1K
A9552	18	120	50	$260	$20.8K

Showing 1–10 of 68

Related Providers

Other providers that share a Tax Identification Number (TIN) with Allan Espinosa Morazan, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Arizona Oncology Associates PC	AZ	Specialist	$0	$13.9M
Pines Health Services	ME	Internal Medicine Physician	$0	$7.6M
Pines Health Services	ME	Obstetrics & Gynecology Physician	$0	$7.1M
Northern Maine Medical Center	ME	Critical Access Hospital	$0	$5.8M
Pines Health Services	ME	Federally Qualified Health Center (FQHC)	$0	$3.7M
Iyad Hamarneh	AZ	Medical Oncology Physician	$3.5M	$0
Northern Maine Medical Center	ME	Rural Health Clinic/Center	$0	$3M
Peter Mathern	AZ	Medical Oncology Physician	$3M	$0
Pines Health Services	ME	Family Medicine Physician	$0	$3M
Northern Maine Medical Center	ME	Rural Health Clinic/Center	$0	$2.8M

Nearby Providers

Other providers in the same ZIP code as Allan Espinosa Morazan, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Yavapai Community Hospital Association	AZ	General Acute Care Hospital	$0	$66.2M
Prescott Healthcare Solutions LLC	AZ	Family Medicine Physician	$0	$13.3M
Summit Behavioral Health Of Az, LLC	AZ	Substance Abuse Rehabilitation Facility	$0	$13.3M
Medical Services Of Prescott, Inc.	AZ	Emergency Medicine Physician	$0	$12.3M
Prescott Whipple Stage	AZ	Taxi	$0	$9.2M
Alan Langerak	AZ	Hematology & Oncology Physician	$2.7M	$0
Prescott Outpatient Surgical Center LLC	AZ	Ambulatory Surgical Clinic/Center	$1.7M	$25.7K
Arizona Institute Of Eye Surgery LLC	AZ	Ambulatory Surgical Clinic/Center	$1.4M	$24.7K
Ayad Agha	AZ	Diagnostic Radiology Physician	$1M	$0
Ajith Purush	AZ	Internal Medicine Physician	$807.3K	$0

Allan Espinosa Morazan — Billing Profile & Reimbursement Data

Sign up for Allan Espinosa Morazan — Billing Profile & Reimbursement Data policy alerts

Allan Espinosa Morazan — Billing Profile & Reimbursement Data

Sign up for Allan Espinosa Morazan — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References